Researchers from Italy’s University of Padua have found that pediatric diabetes patients, ages 5-9, can safely use a child-specific modular model predictive control (or MMPC) for a single-hormone artificial pancreas. This finding came after researchers conducted a randomized, crossover trial that involved 30 children with type 1 diabetes between the ages of 5 and 9.
It was found that when using an artificial pancreas, these kids had a significant reduction in the amount of time they were in hypoglycemia overnight when compared to patients who used parent-managed sensor-augmented pumps. There was also an increase in glucose, but no significant change in their time-in-target.
These findings were published in Diabetes Care on May 10, 2016.